SRR6013490
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.560
- E2F_TARGETS+0.520
- CHOLESTEROL_HOMEOSTASIS+0.450
- OXIDATIVE_PHOSPHORYLATION+0.440
- INTERFERON_ALPHA_RESPONSE+0.430
- G2M_CHECKPOINT+0.420
- PROTEIN_SECRETION+0.400
- MTORC1_SIGNALING+0.390
- INTERFERON_GAMMA_RESPONSE+0.370
- ESTROGEN_RESPONSE_LATE+0.340
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.330
- WNT_BETA_CATENIN_SIGNALING-0.320
- APICAL_JUNCTION-0.230
- KRAS_SIGNALING_DN-0.220
- MYOGENESIS-0.220
- ANGIOGENESIS-0.140
- COAGULATION-0.110
- NOTCH_SIGNALING-0.050
- PI3K_AKT_MTOR_SIGNALING-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | c340b651-bd01-4194-a67b-e801d0feeb2b | — | — | 0.884 |
| 2 | f9c74189-6bdc-49b9-b984-917ffe2b097d | — | — | 0.883 |
| 3 | 8f1213be-da41-4cd6-97b2-f9fce1ea00ff | — | — | 0.855 |
| 4 | SRR5903550 | — | cohortA4 | 0.854 |
| 5 | 8824c0fd-764e-4525-952b-f25efa742772 | — | — | 0.850 |
| 6 | be22f883.ee5e.4632.93d1.661ddc53608e | — | cohortA4 | 0.848 |
| 7 | E97A62A3-E4D3-435C-9165-C0075358578E | — | — | 0.847 |
| 8 | SRR8942975 | — | — | 0.843 |
| 9 | SRR6013496 | — | cohortA4 | 0.842 |
| 10 | bf312cd5-e251-4d63-95b5-c379b3ef5ded | — | — | 0.835 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.560 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.450 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.430 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.340 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.340 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.330 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.320 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.310 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.280 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.260 | Idelalisib | — uncovered |